Your Health, We Care
Koselugo achieved good results in the treatment of neurofibromatosis type I (NF1) and inoperable plexiform neurofibromatosis in a clinical trial published in The New England Journal of Medicine (NEJM).
The results showed that Koselugo effectively inhibited tumor growth, prolonged progression free survival, and had additional benefits in pain reduction, quality of life improvement, and other aspects.
Koselugo is a small molecule inhibitor targeting MEK, which plays the role of a blocker on the mitogen activation link, and its core efficacy is reflected in the inhibition of MEK ···【more】
Article source：Lucius LaosRelease date：2024-08-21Recommended：123
Koselugo is a small molecule MEK inhibitor and a repressor of mitogen activation, and its core role is to inhibit the activation of MEK signaling pathways, thereby effectively inte···【more】
Article source：Lucius LaosRelease date：2024-08-21Recommended：146
Koselugois a small molecule MEK inhibitor (mitogen activation inhibitor), and its main mechanism of action is to block the growth and proliferation of tumor cells by inhibiting the···【more】
Article source：Lucius LaosRelease date：2024-08-21Recommended：103
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
